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Introduction
Graft injury is inevitable during the process of liver transplantation (LT), to which ischemia and reperfusion is an important contributor (1) . In the majority of patients, the manifestations of such graft injury settle rapidly within the first week following LT. However, in a few patients measures of graft function display significant abnormalities, which are referred to as early graft dysfunction (EGD). Patients who develop EGD have increased risk of graft failure or death early in the post-LT period (2) . In its most severe form, primary nonfunction (PNF), the risk of death, or the requirement for emergency liver retransplantation (LRT) within the first 1-2 weeks are markedly increased (3, 4) .
There is a lack of agreement on the terminology used to describe PNF (5) . The diagnostic criteria of PNF also varied significantly in the reported literature (3, 4, (6) (7) (8) (9) (10) . Initial studies suggested the use of markers of liver injury such as aspartate aminotransferase (AST) (3, 4, 6) or alanine aminotransferase (ALT) (3, (6) (7) (8) , or markers of hepatic synthetic function such as prothrombin time (4, (6) (7) (8) bilirubin level, (2) bile production (6, 8) acidosis, (11) ammonia level (4), or hepatic encephalopathy (2) . The timing of measurement of these variables also varies in the literature with variables included on day-1 post-LT (3), first 3 days (8, 12) , to those recorded at any day between days 2-7 posttransplant (4). Furthermore, the time frame of the outcome of PNF varied in the described studies, with death or retransplantation occurring within 1 week, (6) days 2-7 (4), within 10 days (11), or up to 2 weeks post-LT (3, 5) .
In the United Kingdom (UK), the National Health Services (NHS) Blood and Transplant Advisory Committee set the criteria for PNF under category 9 of super-urgent listing for LT (13) . These criteria were based mainly on clinical experience utilizing previously reported data (Box 1). In the United States (US), the Organ Procurement and Transplant Network (OPTN) described a different set of diagnostic criteria for PNF (Box 2) (14) . In both these criteria, cut-off points were arbitrary with significant difference in the choice of thresholds for the two systems. Moreover, the UK criteria include bile production, based on previous practices of LT. Routine use of biliary drains to monitor bile output is rarely in use currently.
The aims of this study were threefold: Firstly, to define diagnostic criteria of PNF using standard and transportable laboratory tests performed within the first week post-LT based on statistical models; secondly, to compare the diagnostic performance of the proposed criteria with the current UK criteria for PNF; and lastly, to internally validate the newly proposed criteria.
Materials and Methods

Patients and design
We performed a retrospective analysis of all adult patients (n = 1286) who had LT in our center and received grafts from deceased donors between January 2000 and December 2008. Exclusions included retransplanted patients (n = 133), those who died during the transplant operation (n = 4), had hepatic artery thrombosis (n = 19) as a cause of graft failure, and 5 patients who had early death secondary to metastatic cancers. Therefore, data were analyzed on 1125 patients.
Dataset
All patients who had LT in our center were admitted from the operating theater to the liver intensive therapy unit (LITU). All patients admitted to the LITU had daily clinical, physiological, and laboratory variables and requirement for organ support prospectively recorded into the LITU database. This dataset, electronic patient record, and the clinical notes were utilized to summate demographic, clinical, and laboratory data at the time of listing, at time of transplant, and for the first week following LT. Variables determined daily included AST, bilirubin, INR, lactate, creatinine, requirement for vasopressors, and renal replacement therapy (RRT).
Prognostic models were calculated at the time of listing and at transplant. Mayo End-Stage Liver Disease (MELD) score was calculated according to the United Network of Organ Sharing (UNOS) adjustments (15) . The UK End-Stage Liver Disease (UKELD) score was calculated according to Barber et al (16) . Donor and graft variables assessed were age, gender, donor-to-recipient gender mismatch, ethnicity, donor-to-recipient blood group mismatch, height, weight, body mass index, graft type: donation after brain death (DBD) versus donation after circulatory death (DCD), organ type (whole vs. nonwhole), and cold ischemia time (CIT). The donor risk index (DRI) was calculated according to Feng et al (17) . Marginal grafts were defined as grafts with DRI > 1.8 (18) . Grafts were also categorized as marginal and nonmarginal according to surgical inspection of the grafts by the unit's transplant surgeons.
Definitions of outcome measures
Patient survival was documented according to their recorded survival status in our hospital information system. According to previously published reports, we chose death or the requirement for LRT within 2 weeks of primary liver transplant (PLT) as the primary outcome to define PNF (3, 5, 19) .
Ethical approval
Ethical approval for interrogation, analysis, and publication of this anonymized dataset was obtained from the Southeast London Research Ethics Committee 3 (previously known as King's College Hospital Research Ethics Committee).
Statistical analysis
Data were assessed for normality using the D'Agostino Pearson test. Comparisons were made by Student's t-test (one-way analysis of variance) or Mann-Whitney (Kruskall-Wallis) for two (or more) comparison groups. Categorical data were compared using the chi-square test. Univariate and multivariate (backwards mode) logistic regression and area under the receiver operating curves (AUROC) analysis were performed for 2-week outcomes. To assess goodness of fit, the Hosmer and Lemeshow test was calculated where a p-value of <0.05 was used to reject variables or models for failing to adequately pass the comparison of observed and expected outcomes due to overfitting. In multivariate regression, backwards mode, the criterion for exclusion was a p-value of 0.15 to balance the need for a parsimonious model while reducing potential bias from suppressor effects. Therefore, a three-stage filtering process was used where a variable was removed if (a) it was radically Box 1. NHS Blood and Transplant Liver Advisory Group diagnostic criteria for super-urgent listing for LT for early graft dysfunction. Early graft dysfunction on days 0-7 after LT with at least two of the following: (a) AST ≥3000 and one or both of the following:
• INR ≥2. 5 • Acidosis, defined as having an arterial pH ≤ 7.30 or venous pH of 7.25 and/or lactate ≥4 mmol/L (b) Anhepatic candidate alterable by therapy, (b) if it failed the Hosmer and Lemeshow test (p < 0.05), and (c) if the p-value was >0.15 on backward regression. Data were assessed for multiple collinearity using correlation coefficients. For an R > 0.4, the predictor with the highest regression coefficient was retained. In order to minimize reductions in specificity while attempting to improve sensitivity, specificity was fixed a priori at 95% in deciding cut-offs for any logistic regression models. A second repeated-measures logistic regression model was fitted where all data were added to the model to assess for any bias in the above variable selection method as described in the supplementary material (Data S1 and Table S1 ). Significance was required at the 95% level with a two-tailed p-value of <0.05. Data were analyzed in Excel (Microsoft, Redmond, WA), SPSS 17 (IBM, Armonk, NY), and MedCalc v 12.2.0 (Mariakerke, Belgium).
Results
Recipient, donor, and graft descriptive results Forty-two patients (3.7%) had graft failure within 2 weeks of PLT. Twenty-four patients (2.1%) died and 18 patients (1.6%) had LRT within 2 weeks of PLT. Recipient characteristics are summarized in Table 1 . There were no significant differences in demographic variables or etiology of liver disease between patients who had 2-week graft failure compared to those who did not, except for a higher proportion of patients transplanted with acute liver failure (ALF) in the 2-week graft failure group. At transplant, patients with graft failure had lower albumin level, and higher bilirubin, creatinine, INR, sodium (Na) levels, and MELD score. Donor and graft variables were not significantly different between the two groups except for higher proportion of ABO mismatch, gender mismatch, and higher donor body mass index (Table 1) . Grafts assessed as nonoptimal had a higher DRI than those assessed as optimal: 1.68 (1.00-3.70) versus 1.61 (0.93-3.90), p = 0.02. Nonoptimal livers had higher day-1 AST 663 (39-13886) versus 568 , p = 0.001. However, no relationship between PNF and graft weight, graft assessment, or blood group was observed. On univariate analysis, these variables did not reach significance and therefore were not included in subsequent multivariable analysis. DRI, proportion of patients with marginal grafts, DCD grafts, partial grafts, and CIT were not significantly different between the two groups.
By expanding the definition of PNF to 2 weeks, a total of 42 cases were identified compared to 27 who met the US definition in this time frame and only 14 who met the UK definition in this time frame.
Posttransplant biochemical data Lactate, AST, bilirubin, INR, and creatinine showed a general trend of decline within the first posttransplant week except for bilirubin and creatinine levels for patients with 2-week graft failure ( Figure 1 ). Lactate, AST, bilirubin, INR, and creatinine were significantly higher in patients who had 2-week graft failure compared to those in whom the graft survived for more than 2 weeks (Table 2 ).
Derivation and validation cohorts
A randomly generated index was used to split the data into derivation and validation cohorts (65% and 35% of the entire cohort, respectively). Data were matched (p > 0.05) between the derivation and validation sets for >95% of variables (Table S1 ).
Factors associated with PNF Univariate and multivariate logistic regression analyses are shown in Table 3 . There were a large number of variables which on univariate analysis could be initially justified in progressing to multivariate analysis based on p-value alone. Of note, DRI and DCD status did not have univariate significance for predicting this short-term outcome. We employed two methods to help simplify the regression model. First, if a variable was prone to bias in terms of being potentially modifiable by treatment (e.g. serum creatinine or decision to continue/start RRT) and second, statistically, if the Hosmer and Lemeshow p-value was <0.05, there was a danger of poor fit in any subsequent model. Using these filters, we identified transplant albumin, day-1 AST, day-1 lactate, day-3 bilirubin, day-3 INR, and day-7 AST as independent factors associated with PNF. Day-1 and day-7 AST were not closely correlated (r = 0.05, p = 0.010). MELD score at transplantation as a continuous or categorical variable with cut-off value of 25 (20, 21) Our model also showed significant improvement in the sensitivity of the model in detecting patients with PNF (73%) compared to the UK (31%) and US (66%) criteria (Table 4) . 
Validation of the new model
Application of the model to recipients of marginal grafts
Published reports on this topic varied in regard to the inclusion or exclusion of groups of patients such as patients with ALF, recipients of DCD grafts, and recipients of partial or split grafts. We compared the diagnostic performance of our model on the entire validation cohort and after exclusion of each of the subgroups mentioned above as illustrated in Figure 4 . The new model continued to perform well after exclusion of recipients of DCD grafts and recipients of partial grafts, but there was a drop in the AUROC from 0.840 to 0.795 after exclusion of patients transplanted for ALF. Despite the decrease in AUROC, our model continued to discriminate well between those who met the outcome definition of PNF from those who did not (p = 0.041). 
Effect of renal support
When modeled with the dichotomous variable of whether the patient received hemofiltration on that day, only continuous veno-venous hemodiafiltration on day 7
was independently associated with PNF and therefore was added into the model. The modified model had an AUROC of 0.828, so there was no benefit in its addition. Addition of serum creatinine from all measured posttransplant days did not improve the model, and none of the creatinine measurements were statistically significant in terms of prognostic performance when forced into logistic regression models.
Assessment of proposed model versus repeatedmeasures logistic regression
We also performed a repeated-measures logistic regression model, initially with all independent variables entered. The final model included AST, lactate, bilirubin, and requirement for vasopressor therapy with highly significant predictive accuracy and a sensitivity of 71 (55-84)% and specificity of 95 (92-97)%. This was essentially the same as with the original proposed model.
Discussion
The diagnostic criteria for PNF in the United Kingdom are described under category 9 of super-urgent listing for retransplantation under the title of EGD (13) . These criteria were based on clinical experience and LT practices of approximately 2 decades ago. During the last 20 years, significant progress was achieved in the field of LT such as improvements in operative methods, immunosuppression, and postoperative intensive care unit (ICU) care (23) . This resulted in the current 1-and 5-year survival rates posttransplant of 90% and >50%, respectively. Despite this improvement, 2.7-6.9% can develop PNF with high early posttransplant mortality without retransplantation (3, 4, 7) . This is the largest study to date to investigate the diagnostic criteria of primary liver graft nonfunction. This study has a number of design strengths compared to previous reports that are worth exploring (3, 4, 7, 8) . First, we set our diagnostic method based on a composite of outcome variables of death and retransplantation rather than categorizing graft function according to laboratory variables. Second, we chose the time interval of the composite outcome measure of 2-week posttransplant to include patients who met the current UK diagnostic criteria by the end of the first week who would have been retransplanted or died within the second week. This was also in agreement with the Strasberg et al suggestion on extending the time interval for the diagnosis of PNF from 1-week to 2-week outcome in an attempt to refine the definition of PNF, and in agreement with other authors (3, 5, 19) . Third, this study focused on adult patients to avoid any heterogeneity in the patient population, whereas previous studies included adults and pediatric patients. Fourth, we excluded patients who developed graft dysfunction or died because of hepatic artery thrombosis, those who died during the transplant procedure, and patients who developed graft dysfunction or died following a second or subsequent transplant, which homogenize the patient population.
The rate of PNF according to the definition in this study was 3.7%, which is significantly lower than 5.8% reported by Johnson and colleagues utilizing the Scientific Registry of Transplant Recipients (SRTR) database of >10 000 patients and lower than 6-9.2% reported by single-center series (19, 24, 25) . We identified a large number of variables that were associated with graft failure on univariable analysis in addition to those documented in Table 4 such as requirement for RRT, creatinine level, requirement for vasopressors, and mechanical ventilation during the first week posttransplant. However, we excluded modifiable variables such as the requirements for RRT, creatinine level, or vasopressor support and other variables that might simply reflect a severity of illness such as requirement for mechanical ventilation in critically ill patients. Other variables were excluded according to statistical methods (goodness of fit).
There is evidence that the severity of recipient illness may have an impact on early posttransplant outcomes. High MELD score at transplantation (cut-off values 25 or 30) was associated with reduced 3-and 12-month posttransplant survival (20) (21) (22) 26) . Our analysis showed that neither MELD (as continuous or categorical variable) nor its components were associated with PNF after controlling for other pre-and posttransplant variables. This finding was consistent with Johnson et al, who used the same definition of PNF in an analysis of SRTR database of 10 545 patients and showed no association of MELD with PNF. Furthermore, the rate of PNF after the implementation MELD score for listing in the United States was relatively stable at approximately 6%, which indicates that despite transplanting sicker patients, the rate of PNF did not change (19) . However, our model included serum albumin at transplantation as a surrogate marker of recipient severity of illness. Serum albumin is one of the five components of the well-established Child-Turcotte-Pugh model, a system used over 4 decades to assess severity of illness in patients with chronic liver disease (27) . More recently, serum albumin was found to have an inverse linear relationship to waiting list (WL) mortality, on analyzing UNOS database and in a single Canadian transplant cohort. Albumin was independent of MELD in predicting WL mortality. Moreover, the addition of serum albumin to MELD and MELDNa (5-variable MELD) significantly improved its ability to identify patients at risk of death on the transplant WL (28) (29) (30) .
We constructed our model for the diagnosis of PNF based on easily obtainable laboratory parameters during the first posttransplant week. Our multivariable regression model identified albumin level at transplant, day-1 blood lactate and AST levels, day-3 bilirubin and INR levels, and day-7 AST as factors independently associated with PNF. Blood lactate is already in use as part of the diagnostic criteria for PNF in the United Kingdom and United States (13, 14) . Blood lactate is a by-product of anaerobic metabolism secondary to abnormal tissue microcirculatory perfusion and oxygenation (31) . It is mainly metabolized by the liver and therefore, higher blood lactate levels may reflect both increased production and impaired clearance in patients with hepatic dysfunction (32) . Unsurprisingly, AST and INR were included in our model based on statistical methods. High AST levels posttransplant indicates acute graft injury and INR reflects the graft synthetic function and are both included in the current UK and US criteria for PNF (13, 14) . We identified bilirubin level as an independent factor associated with PNF. Although bilirubin is not included in the current UK or US criteria for PNF, bilirubin was associated with graft dysfunction in previous reports (2, 9, 33) .
It is believed that earlier liver retransplantation of patients with graft failure within the first posttransplant week carries higher survival compared to retransplantation between the second to fourth weeks (24, 34) . Giving the importance of early diagnosis of PNF, we modified our model to include variables from the first 3 post-LT days.
The modified model showed good diagnostic performance with AUROC of 0.82, which was not significantly different from AUROC of 0.83 for the original model, which utilizes day-7 variables. This indicates that the modified model can detect patients with PNF as early as the third postoperative day. Should these criteria become utilized for super-urgent listing, it can facilitate earlier listing of patients with PNF for LRT.
The diagnostic performance of our model was excellent when applied to the derivation cohort with AUROC 0.912. Although there was a reduction in the diagnostic performance of the model when applied to the validation cohort with AUROC of 0.83, the model had very good diagnostic performance compared to existing UK and US diagnostic criteria (35) . We demonstrated a significant improvement in the sensitivity of this model (73%) compared to the existing UK (31%) and US diagnostic criteria for PNF (66%). This was achieved without significant reduction in specificity of 95% compared to specificity of 93% and 98% for both US and UK criteria, respectively. This model also has significantly improved negative likelihood ratio (LK-) of 0.3 compared to existing models of 0.7 and 0.6 for UK and US PNF models, respectively, indicating superior discrimination of our model in ruling out cases that did not meet the outcome definition of 2-week graft failure, assuming the model is subsequently validated (36) .
Initial poor function of the graft may be attributed to donor or graft variables (3, 4, 37) . Therefore, we applied our model to the validation cohort before and after exclusion of recipients of DCD organs and patients who received partial grafts. The performance of the new model assessed by ROC characteristics did not alter significantly with AUROC of 0.840, 0.854, and 0.821, respectively. This indicates that this model can be applied to recipients of all graft types (marginal and nonmarginal) without significant difference in its diagnostic performance. Furthermore, none of the donor or graft variables including the use of marginal grafts with DRI > 1.8 was associated with PNF on logistic regression. The reported literature varied with regard to the impact of graft and donor quality on the development of PNF. Makowka et al found no impact of donor variables on the development of PNF (7). Others found split or reduced grafts, advanced fatty changes in the graft, longer cold or warm ischemia times, older donor age, donor renal insufficiency, ICU length of stay >3 days, donor weight >100 kg, duration of the anhepatic phase, and DCD grafts were associated with poor graft function (3, 4, 19, (37) (38) (39) . Findings of these reports are difficult to compare to ours for a number of reasons. Firstly, different local practices of donor-recipient matching; secondly, different definitions of PNF (as diagnostic criteria or time frame), and lastly, different era of transplant practices in some of these studies.
There are several limitations to this study. Firstly, it represents a single-center experience and therefore, applicability of the results to other patient populations may be limited. Secondly, operative data such as operation time, volume of blood loss, intraoperative transfusion requirements, preservation solutions used, and warm ischemia time were not available to us and accordingly were not included in our analysis. These variables could be associated with early posttransplant outcomes (3, 4, 8, 40) . Finally, data on immunosuppression were not included in this study; however, all patients received standard immunosuppression according to our institution guidelines.
It is interesting that using a more formal approach to repeated measures without significant supervised variable selection led to a model with similar prognostic accuracy. The model we propose is a relatively simple equation and unless these more data-driven techniques can provide much higher accuracy, we do not recommend them at present. Also, they require data to day 7, whereas our model can allow stratification at day 3 where prompt preparations for retransplantation can be started.
While we performed several steps to statistically validate the findings of our analysis and model, this should not be taken as a final external validation. Particularly since we define PNF in a novel manner, an assessment of improved accuracy and/or survival at several centers would need to be made before changes in practice can be recommended. We make a distinction between PNF and end-stage graft dysfunction beyond 2 weeks posttransplant, which is likely to present as a different clinical entity (putatively called EGD). For our PNF model, rapid assessment and decisions regarding retransplant can be biased by clinical decisions made outside the modeled parameters, and therefore we invite and recommend more robust external validation of the increased sensitivity suggested by our model.
Given that there are differing definitions of PNF between Europe, North America, and Asia, it would be particularly useful to validate the findings of this score in other centers first in the United Kingdom and then internationally to assess any bias both from our approach and those where relisting decisions for PNF use alternative criteria.
In conclusion, this study addresses a life-threatening complication of LT (PNF) and revisits the diagnostic criteria of this complication in the MELD and UKELD era based on acceptable outcome definition. Our proposed criteria utilize easily obtainable and objective laboratory parameters, and they are based on statistical methods. Furthermore, we have shown that our criteria can be modified to obtain earlier diagnosis of PNF with preservation of its diagnostic performance. Our diagnostic criteria are also applicable to recipients of all types of grafts (marginal and nonmarginal). We invite the transplant community in the United Kingdom to externally validate our model to improve the current diagnostic criteria for PNF.
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